Therefore, additional studies in immunocompetent models of natural infection and/or CHB patient biopsies will be required in order to define the relative contribution of intrahepatic NK and virus-specific CD8+ T cells to IFN-α treatment response. The gene discussed is IFNA1; the disease is infection.